Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 7 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 11372008

    Blood factor monitoring assay and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted
  2. US 11365230

    Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof

    IMMUNE DESIGN CORP. · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted
  3. US 11365394

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted
  4. US 11357839

    Brachyury protein, non-poxvirus non-yeast vectors encoding Brachyury protein, and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted
  5. US 11352639

    Gene therapy based on vector VTVAF17

    OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU “ALLEL TSENTR INNOVATSIONNYKH BIOTEKHNOLOGY” · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  6. US 11351177

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  7. US 11345928

    Modified immunization vectors

    THE ARIZONA BOARD OF REGENTS · Granted May 31, 2022 · Expires May 26, 2042

    granted
  8. US 11344557

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted May 31, 2022 · Expires May 26, 2042

    granted
  9. US 11332727

    Method for reducing an immune response by administering an immune evading adeno-associated AAV8 or AAVDJ viral vector

    The Regents of the University of California · Granted May 17, 2022 · Expires May 12, 2042

    granted
  10. US 11311549

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted
  11. US 11299533

    Purification of factor VIII subspecies

    Takeda Pharmaceutical Company Limited · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted
  12. US 11286528

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted
  13. US 11273182

    Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted
  14. US 11274282

    Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen

    The Board of Regents of the University of Texas System · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted
  15. US 11274294

    TAL effector-mediated DNA modification

    Regents of the University of Minnesota · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted
  16. US 11266720

    Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted
  17. US 11267782

    Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2α inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted
  18. US 11266724

    Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

    Catalyst Biosciences, Inc. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted
  19. US 11261237

    Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Mar 1, 2022 · Expires Feb 24, 2042

    granted
  20. US 11254739

    Anti-human migration stimulating factor (MSF) and uses thereof

    HUMANITAS MIRASOLE S.P.A. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  21. US 11254731

    Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

    Takeda Pharmaceutical Company Limited · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  22. US 11241478

    Adenovirus-associated viral vectors for expressing variants of tetratricopeptide repeat (TPR)-containing Rab8b interacting (TRIP8b) protein in neurons and uses thereof for treating major depressive disorder (MDD)

    Northwestern University · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  23. US 11236100

    Modulators of eukaryotic initiation factor 2B, compositions and methods

    DENALI THERAPEUTICS INC. · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted
  24. US 11225514

    Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)

    The Regents of the University of California · Granted Jan 18, 2022 · Expires Jan 13, 2042

    granted